Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
By: Brian T Helfand, Haitao Chen, Richard J Fantus, Carly A Conran, Charles B Brendler, Siquan Lilly Zheng, Patrick C Walsh, William B Isaacs, Jianfeng Xu

Division of Urology, John and Carol Walter for Urologic Health, NorthShore University HealthSystem, Evanston, Illinois.
2018-04-19; doi: 10.1002/pros.23664
Abstract

Purpose

Family history assigns equivalent risk to all relatives based upon the degree of relationship. Recent genetic studies have identified single nucleotide polymorphisms (SNPs) that can be used to calculate a genetic risk score (GRS) to determine prostate cancer (PCa) risk. We sought to determine whether GRS can stratify PCa risk among individuals in families considered to be at higher risk due their family history of PCa.

Materials

Family members with hereditary PCa were recruited and genotyped for 17 SNPs associated with PCa. A GRS was calculated for all subjects. Analyses compared the distribution of GRS values among affected and unaffected family members of varying relationship degrees.

Results

Data was available for 789 family members of probands including 552 affected and 237 unaffected relatives. Median GRSs were higher among first-degree relatives compared to second- and third-degree relatives. In addition, GRS values among affected first- and second-degree relatives were significantly higher than unaffected relatives (P = 0.042 and P = 0.016, respectively). Multivariate analysis including GRS and degree of relationship demonstrated that GRS was a significant and independent predictor of PCa (OR 1.52, 95%CI 1.15-2.01).

Conclusion

GRS is an easy-to-interpret, objective measure that can be used to assess differences in PCa risk among family members of affected men. GRS allows for further differentiation among family members, providing better risk assessment. While prospective validation studies are required, this information can help guide relatives in regards to the time of initiation and frequency of PCa screening.



© 2018 Wiley Periodicals, Inc.

PMID:29923209






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements